(68)Ga-PSMA-11 PET/CT versus (68)Ga-PSMA-11 PET/MRI for the detection of biochemically recurrent prostate cancer: a systematic review and meta-analysis

PURPOSE: Our aim was to conduct a meta-analysis and systematic review in order to compare the diagnostic efficacy of (68)Ga-PSMA-11 PET/CT and (68)Ga-PSMA-11 PET/MRI in patients with biochemically recurrent after radical prostatectomy and biochemically recurrent prostate cancers (BCR) after hybrid RT and RP. METHODS: Up until February 2023, we searched PubMed, Embase, and Web of Science for pertinent papers. Studies examining the utility of (68)Ga-PSMA-11 PET/CT or PET/MRI as a screening tool for biochemically recurrent prostate cancer were included. To measure heterogeneity, we employed the I(2) statistic. In cases of substantial heterogeneity (I(2) > 50%), we used the random effect model to produce a forest plot. In other cases, we utilized the fixed model. Furthermore, we assessed the quality of the studies included using the Quality Assessment of Diagnostic Performance Studies (QUADAS-2) method. RESULTS: In total, 37 studies involving 8409 patients were examined. For (68)Ga-PSMA-11 PET/CT and (68)Ga-PSMA-11 PET/MRI, the combined total detection rate was 0.70 (95% CI: 0.65-0.75) and 0.71 (95% CI:0.67-0.75), respectively. (68)Ga-PSMA-11 PET/CT and (68)Ga-PSMA-11 PET/MRI did not substantially differ in terms of the overall detection rate for BCR (P = 0.58). The detection rate was unaffected by the PSA values (all P > 0.05). CONCLUSION: The diagnostic efficacy of (68)Ga-PSMA-11 PET/CT appears to be equivalent to that of (68)Ga-PSMA-11 PET/MRI in detecting biochemically recurrent prostate cancer. Nonetheless, it should be noted that not all studies have used pathological biopsies as the gold standard. Therefore, additional larger prospective studies are needed to address this issue. SYSTEMATIC REVIEW REGISTRATION: identifier CRD42023410039.